A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer

Charalampos S. Floudas, Gagandeep Brar, Donna Mabry-Hrones, Austin G. Duffy, Bradford Wood, Elliot Levy, Venkatesh Krishnasamy, Suzanne Fioravanti, Cecilia M. Bonilla, Melissa Walker, Maria Pia Morelli, David E. Kleiner, Seth M. Steinberg, William D. Figg, Tim F. Greten, Changqing Xie*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

Background: The prognosis of metastatic colorectal cancer (mCRC) is poor. We assessed the feasibility, safety, and efficacy of the anti-programmed cell death 1 fusion protein AMP-224 in combination with low-dose cyclophosphamide and stereotactic body radiation (SBRT) treatment in patients with mCRC refractory to standard chemotherapy. Patients and Methods: Fifteen patients were enrolled. Six received SBRT 8 Gy on day 0 (dose level 1), whereas 9 received 8 Gy on days −2 to day 0. All received cyclophosphamide 200 mg/m2 intravenously (I.V.) on day 0. On day 1, both groups received AMP-224 10 mg/kg I.V., repeated every 2 weeks for a total of 6 doses. Primary end points were feasibility and safety. Results: Ten (67%) patients completed 6 doses of AMP-224; 5 patients (33%) discontinued treatment because of disease progression. No dose-limiting toxicity was observed; 9 patients (60%) experienced treatment-related adverse events, all Grade 1 or 2. No objective response was noted; 3 patients (20%) had stable disease. Median progression-free survival and overall survival were 2.8 months (95% confidence interval [CI], 1.2-2.8 months) and 6.0 months (95% CI, 2.8-9.6 months), respectively. M2 macrophage polarization was present in the pretreatment tumor biopsy samples, but not post-treatment samples. Conclusion: AMP-224 in combination with SBRT and low-dose cyclophosphamide was well tolerated, however, no significant clinical benefit was observed in patients with mCRC.

Original languageEnglish
Pages (from-to)e349-e360
JournalClinical Colorectal Cancer
Volume18
Issue number4
DOIs
StatePublished - Dec 2019
Externally publishedYes

Keywords

  • Immunotherapy
  • Macrophages
  • PD-L2 Ligand
  • Programmed Cell Death 1 Protein
  • Stereotactic Radiation Therapy

Fingerprint

Dive into the research topics of 'A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

Cite this